This HTML5 document contains 65 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n16http://linked.opendata.cz/resource/drugbank/company/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01025/identifier/chemspider/
n18http://bio2rdf.org/drugbank:
n6http://linked.opendata.cz/resource/drugbank/drug/DB01025/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n21http://linked.opendata.cz/resource/drugbank/patent/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01025/identifier/pharmgkb/
n15http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n22http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n19http://linked.opendata.cz/ontology/mesh/
n7http://linked.opendata.cz/ontology/drugbank/
n25http://linked.opendata.cz/resource/drugbank/drug/DB01025/identifier/pubchem-compound/
n24http://www.drugs.com/cdi/
n12http://linked.opendata.cz/resource/drugbank/property/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01025/identifier/pubchem-substance/
xsdhhttp://www.w3.org/2001/XMLSchema#
n5http://linked.opendata.cz/resource/drugbank/drug/DB01025/identifier/kegg-drug/
n4http://linked.opendata.cz/resource/drugbank/drug/DB01025/identifier/drugbank/
n9http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01025
rdf:type
n7:Drug
n7:description
Amlexanox is an antiallergic drug, clinically effective for atopic diseases, especially allergic asthma and rhinitis. Amlexanox as a topical paste is a well tolerated treatment of recurrent aphthous ulcers. Recurrent aphthous ulcer (RAU) is the most prevalent oral mucosal disease in humans, estimated to affect between 5% and 50% of the general population.
n7:generalReferences
# Bell J: Amlexanox for the treatment of recurrent aphthous ulcers. Clin Drug Investig. 2005;25(9):555-66. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17532700
n7:group
approved investigational
n7:halfLife
Elimination half-life is 3.5 ± 1.1 hours.
n7:indication
Used as a paste in the mouth to treat aphthous ulcers (canker sores).
owl:sameAs
n15:DB01025 n18:DB01025
dcterms:title
Amlexanox
adms:identifier
n4:DB01025 n5:D01828 n6:31205 n10:2076 n13:46504508 n17:PA164745310 n25:2161
n7:mechanismOfAction
As a benzopyrano-bipyridine carboxylic acid derivative, amlexanox has anti-inflammatory and antiallergic properties. It inhibits chemical mediatory release of the slow-reacting substance of anaphylaxis (SRS-A) and may have antagonistic effects on interleukin-3. When cells are under stress, they release an inactive form of human fibroblast growth factor 1 (FGF-1), a potent mitogen (entity that causes mitosis). Amlexanox binds to FGF1, increasing its conformational stability, sterically blocking Cu(2+) induced oxidation which normally leads to activation of FGF-1.
n7:packager
n16:271B555F-363D-11E5-9242-09173F13E4C5 n16:271B5560-363D-11E5-9242-09173F13E4C5 n16:271B555D-363D-11E5-9242-09173F13E4C5 n16:271B555E-363D-11E5-9242-09173F13E4C5
n7:patent
n21:5362737
n7:synonym
Amlexanox 2-Amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3-b)pyridine-3-carboxylic acid Amlexanoxo Amlexanoxum Amoxanox
n19:hasConcept
n20:M0132876
foaf:page
n24:amlexanox.html
n7:IUPAC-Name
n12:271B5567-363D-11E5-9242-09173F13E4C5
n7:InChI
n12:271B556D-363D-11E5-9242-09173F13E4C5
n7:Molecular-Formula
n12:271B556C-363D-11E5-9242-09173F13E4C5
n7:Molecular-Weight
n12:271B5569-363D-11E5-9242-09173F13E4C5
n7:Monoisotopic-Weight
n12:271B556A-363D-11E5-9242-09173F13E4C5
n7:SMILES
n12:271B556B-363D-11E5-9242-09173F13E4C5
n7:Water-Solubility
n12:271B5565-363D-11E5-9242-09173F13E4C5
n7:logP
n12:271B557D-363D-11E5-9242-09173F13E4C5 n12:271B5563-363D-11E5-9242-09173F13E4C5 n12:271B5566-363D-11E5-9242-09173F13E4C5
n7:logS
n12:271B5564-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n9:R03DX01 n9:A01AD07
n7:H-Bond-Acceptor-Count
n12:271B5573-363D-11E5-9242-09173F13E4C5
n7:H-Bond-Donor-Count
n12:271B5574-363D-11E5-9242-09173F13E4C5
n7:InChIKey
n12:271B556E-363D-11E5-9242-09173F13E4C5
n7:Polar-Surface-Area--PSA-
n12:271B556F-363D-11E5-9242-09173F13E4C5
n7:Polarizability
n12:271B5571-363D-11E5-9242-09173F13E4C5
n7:Refractivity
n12:271B5570-363D-11E5-9242-09173F13E4C5
n7:Rotatable-Bond-Count
n12:271B5572-363D-11E5-9242-09173F13E4C5
n7:absorption
No significant absorption directly through the active ulcer. Most of the systemic absorption is via the gastrointestinal tract.
n7:affectedOrganism
Humans and other mammals
n7:casRegistryNumber
68302-57-8
n7:category
n7:containedIn
n22:271B5561-363D-11E5-9242-09173F13E4C5 n22:271B5562-363D-11E5-9242-09173F13E4C5
n7:Bioavailability
n12:271B5579-363D-11E5-9242-09173F13E4C5
n7:Ghose-Filter
n12:271B557B-363D-11E5-9242-09173F13E4C5
n7:MDDR-Like-Rule
n12:271B557C-363D-11E5-9242-09173F13E4C5
n7:Number-of-Rings
n12:271B5578-363D-11E5-9242-09173F13E4C5
n7:Physiological-Charge
n12:271B5577-363D-11E5-9242-09173F13E4C5
n7:Rule-of-Five
n12:271B557A-363D-11E5-9242-09173F13E4C5
n7:Traditional-IUPAC-Name
n12:271B5568-363D-11E5-9242-09173F13E4C5
n7:pKa--strongest-acidic-
n12:271B5575-363D-11E5-9242-09173F13E4C5
n7:pKa--strongest-basic-
n12:271B5576-363D-11E5-9242-09173F13E4C5